Bioequivalence Study of Aqueous Humour Concentrations of Active Ingredients Following Topical Application of LEVIOSA® Versus F2904 in Cataract Surgery Patients

The primary objective of this study is to evaluate the **bioequivalence** of aqueous humour concentrations of active ingredients following the topical application of LEVIOSA® compared to F2904 in patients undergoing **cataract** surgery. This assessment is clinically relevant as it aims to determine whether the two formulations deliver similar therapeutic effects, which is crucial for ensuring effective treatment options for patients with cataracts. The study is designed as a randomized, parallel-group, blinded-assessor trial to ensure unbiased and reliable results.

The clinical trial focuses on participants diagnosed with **cataract**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial involves a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants were selected based on criteria that are not explicitly detailed in the available data. Lifestyle considerations such as diet, physical activity, or habits have not been specified. The trial aims to gather insights from a diverse group, ensuring representation across different age groups and genders.

The clinical trial is designed to evaluate the **bioequivalence** of aqueous humour concentrations of active ingredients following the topical application of two formulations in patients undergoing cataract surgery. This study is structured as a randomized, parallel-group, blinded-assessor trial, ensuring that the assessment of outcomes is unbiased and that participants are randomly assigned to treatment groups. The trial is set to commence recruitment on January 1, 2024, and is anticipated to conclude by March 31, 2025, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as a screening to determine eligibility based on predefined criteria. This visit will involve a thorough assessment to ensure that participants meet the necessary conditions for inclusion in the study. Following the initial visit, participants will attend scheduled follow-up visits, which are critical for monitoring the effects of the treatment and ensuring participant safety. These visits will include assessments of the primary and secondary endpoints, although specific endpoints are not detailed in the available data. The study will culminate in an end-of-study visit, where final evaluations will be conducted to assess the overall outcomes of the trial.

The expected duration of participant involvement will align with the overall trial timeline, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience adverse effects, fail to comply with study protocols, or withdraw consent. The trial is categorized as a Phase 2 study, focusing on the efficacy and safety of the interventions in a controlled environment. The study's design and procedures are meticulously planned to ensure the collection of reliable and valid data, contributing to the understanding of treatment effects in patients with **cataract**.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 2 study, which typically focuses on assessing the efficacy of a treatment, as well as further evaluating its safety. The trial is scheduled to commence recruitment on January 1, 2024, with an estimated completion date of March 31, 2025. Although specific efficacy parameters or endpoints are not detailed, Phase 2 trials generally involve measuring clinical outcomes that are relevant to the disease being studied. These may include symptom improvement scores, biomarker levels, or disease remission rates, depending on the condition under investigation. The methods for measuring and analyzing these parameters are typically standardized and may involve validated scales, laboratory tests, or patient-reported outcomes collected at predefined timepoints throughout the study. The trial's design and execution will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the efficacy assessments.